Jade Biosciences, Inc. JBIO
Set alert
13.93 USD -0.13 -0.92%
At close · Nov 2
13.93 0.00 0.00%
After hours · Nov 2, 4:00 PM ET
13.55 Day range 14.44
8.36 52-week range 28.00
- YTD
- -9.72%
- 1 year
- +42.14%
- Open
- 14.11
- Prev close
- 14.06
- Mkt cap
- 885.91M
- Vol
- 718.19K
- Avg vol
- 898.85K
- EPS
- -1.92
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 13.55
- High
- 14.44
- Forward P/E
- -6.29
- Beta
- 0.00
- Short ratio
- 12.92
- Inst. own
- 116.01%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 12, 2026
- 50-d avg
- 20.55
- 200-d avg
- 18.29
- 1y target
- 50.13
Key statistics
- Market cap
- 1.07B
- Enterprise value
- 604.81M
- Trailing P/E
- 0.00
- Forward P/E
- -6.29
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 2.42
- EPS (TTM)
- -1.07
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 461.20M
- Total debt
- 1.39M
- Return on equity
- 0.00%
- Shares outstanding
- 63.60M
- Short % of float
- 19.23%
- 50-day average
- 20.55
- 200-day average
- 18.29
Analyst view
Consensus: none
Price target (mean) 50.13 +259.8% upside
Now 13.93
- Target (low)
- 40.00
- Target (mean)
- 50.13
- Target (high)
- 77.00
Ratings (0m) 10 10 buy · 0 hold · 0 sell
- Strong buy0
- Buy10
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 12, 2026
Expected Nov 12, 2026. Consensus EPS estimate -0.78642.
Financials — quick view
JBIO Revenue — quarterly 0
JBIO Net income — quarterly -55.77M
JBIO EPS — quarterly -0.76
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2026 | Sep 30, 2026 | -0.73 | — | — | — |
| Aug 10, 2026 | Jun 30, 2026 | -0.63642 | -0.76 | -0.12 | -19.42% |
| May 7, 2026 | Mar 31, 2026 | -0.52 | -0.57 | -0.05 | -9.62% |
| Mar 6, 2026 | Dec 31, 2025 | -0.45 | -0.45 | 0.00 | 0.00% |
| Nov 14, 2025 | Sep 30, 2025 | -0.57 | -0.48 | +0.09 | +15.79% |
| Aug 14, 2025 | Jun 30, 2025 | -0.43 | -0.86 | -0.43 | -100.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 11, 2026 | Wedbush | main | Outperform | Outperform |
| Aug 10, 2026 | BTIG | main | Buy | Buy |
| Jun 15, 2026 | UBS | init | — | Buy |
| Jun 2, 2026 | Wedbush | main | Outperform | Outperform |
| Jun 1, 2026 | BTIG | main | Buy | Buy |
| Jun 1, 2026 | HC Wainwright & Co. | main | Buy | Buy |
About Jade Biosciences, Inc.
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- jadebiosciences.com
News
- BTIG Reiterates Buy on Jade Biosciences, Maintains $77 Price Target
- Jade Biosciences to Highlight Advancement of JADE101 Development Program at American Society of Nephrology (ASN) Kidney Week 2026
- Wedbush Reiterates Outperform on Jade Biosciences, Maintains $47 Price Target
- HC Wainwright & Co. Reiterates Buy on Jade Biosciences, Maintains $55 Price Target
- Jade Biosciences, Inc. (JBIO) Discusses JADE301 Program Profile and Preclinical Data in Dermatomyositis Transcript
- Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026
- Jade Biosciences, Inc. (NASDAQ:JBIO) Stock Has Average Target Price of $51.75 According to Brokerages
- Jade Biosciences, Inc. (JBIO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
- Jade Biosciences to Participate in Upcoming Conferences
- Jade Biosciences: Duration Is The Real Product
Your note
Sign in to keep a note on JBIO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BALTA ELIZABETH | Officer | Stock Award(Grant) | Feb 11, 2026 | 28,125 |
| DAHMS BRADFORD D | Chief Financial Officer | Stock Award(Grant) | Feb 11, 2026 | 37,813 |
| FAIRMOUNT FUNDS MANAGEMENT LLC | Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Oct 5, 2025 | 0 |
| FROHLICH TOM | Chief Executive Officer | Stock Award(Grant) | Feb 11, 2026 | 86,331 |
| KING ANDREW JAMES | Officer | Stock Award(Grant) | Feb 11, 2026 | 386,113 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 14.35% | 9,126,877 | 152.97M | Jun 29, 2026 |
| Jupiter Topco LLC | 9.86% | 6,273,262 | 105.14M | Jun 29, 2026 |
| Fairmount Funds Management LLC | 7.16% | 4,553,494 | 76.32M | Jun 29, 2026 |
| RA Capital Management, L.P. | 5.77% | 3,671,083 | 61.53M | Jun 29, 2026 |
| Venrock Adviser, LLC | 5.06% | 3,220,364 | 53.97M | Jun 29, 2026 |
| Bellevue Group AG | 4.81% | 3,057,996 | 51.25M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.67% | 1,699,343 | 28.48M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.37% | 1,506,416 | 25.25M | Jul 30, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 1.87% | 1,191,884 | 19.98M | Jul 30, 2026 |
| Fidelity Capital Trust-Fidelity Stock Selector Small Cap Fund | 1.43% | 908,146 | 15.22M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.31% | 833,590 | 13.97M | Jul 30, 2026 |
| Fidelity Select Portfolios-Select Health Care Portfolio | 1.29% | 819,578 | 13.74M | Jul 30, 2026 |